This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT
Scientific Reports Open Access 27 February 2018
-
A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?
Leukemia Open Access 31 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.
Markovic A, MacKenzie KL, Lock RB . FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol 2005; 37: 1168–1172.
Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260–263.
Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014; 123: 94–100.
Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984–2992.
Ahmad R, Liu S, Weisberg E, Nelson E, Galinsky I, Meyer C et al. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res 2010; 8: 986–993.
Wander SA, Levis MJ, Fathi AT . The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol 2014; 5: 65–77.
Warkentin AA, Lopez MS, Lasater EA, Lin K, He BL, Leung AY et al. Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. Elife 2014; 3: 03445.
Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C et al. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 2015; 30: 754–757.
Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329–336.
Acknowledgements
JL, QL and WW are supported by the grant of ‘Cross-disciplinary Collaborative Teams Program for Science, Technology and Innovation (2014−2016)’ from Chinese Academy of Sciences. ZZ is supported by Anhui Province Natural Science Foundation Annual Key Program (grant number: 1301023011). We thank China ‘Thousand Talents Program’ support for QL and ‘Hundred Talents Program’ of The Chinese Academy of Sciences support for JL and WW. ZZ is supported by Key Projects of Provincial Natural Science Research in Colleges and Universities of Anhui Province (grant number: KJ2014Z017). JL is also supported by the National Program for Support of Top-notch Young Professionals. QL is also supported by the CAS/SAFEA International Partnership Program for Creative Research Teams.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Dr. Shanchun Zhang is shareholder of Hefei Cosource Medicine Technology Co. LTD.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Wu, H., Wang, A., Qi, Z. et al. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia 30, 2112–2116 (2016). https://doi.org/10.1038/leu.2016.151
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.151
This article is cited by
-
Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models
Investigational New Drugs (2020)
-
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT
Scientific Reports (2018)
-
A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?
Leukemia (2017)